Flatidyl

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flatidyl

Quick Facts

Property Description
Active Ingredient Simethicone (Simeticone)
Form Tablet, Capsule, Liquid Suspension
Pharmacological Class Antiflatulent / Non-Systemic Gastrointestinal Agent
General Purpose Relief from symptoms of excess gas and bloating
Origin Synthetic (Silicone-based polymer)

What is Flatidyl? Definition and Active Composition

Flatidyl is a commercial medicine whose single active ingredient is Simethicone, also recognized internationally as Simeticone. Chemically, Simethicone is a synthetic, silicone-based polymer. It is officially classified as an antiflatulent, identifying it as a medicine specifically intended for managing discomfort associated with the presence of excess gas within the digestive system. Simethicone is a compound used for providing symptomatic relief from gas accumulation, which is a common occurrence after heavy meals or in cases of functional digestive upset.


Mechanism of Action and Non-Systemic Profile

Simethicone's action is fundamentally physical and operates locally within the gastrointestinal (GI) tract by acting as an antifoaming agent. It functions by reducing the surface tension of the numerous, small gas bubbles trapped in the stomach and intestines. This physical change causes the bubbles to coalesce into larger gas pockets, facilitating their natural elimination. The general therapeutic purpose is to ease the feeling of bloating, pressure, and abdominal discomfort.

A critical aspect of its profile is that the substance is non-systemic: it is physiologically inert and is neither absorbed into the bloodstream nor metabolized by the body. The substance is excreted unchanged in the feces, a characteristic of its localized action within the digestive tract. Flatidyl, as a single-ingredient formulation, is provided for oral administration in forms such as tablets, capsules, and liquid suspensions.

Regulatory References

  1. National Library of Medicine (NIH) confirmed the medicine's role in providing symptomatic relief from gas accumulation

What side effects are possible with Flatidyl?

Possible side effects and safety information

The safety profile of Flatidyl (Simethicone) is structurally defined by its classification as a physiologically inert and non-systemic compound; it is not absorbed into the bloodstream. Adverse reactions are generally localized and uncommon, as documented in regulatory sources.


Adverse Reaction Scope Official Regulatory Statement
Key Adverse Reaction Categories Hypersensitivity reactions and minor local Gastrointestinal (GI) disturbances.
Frequency Classification Minor GI effects (e.g., nausea, constipation, diarrhea) are typically listed as Uncommon or with Frequency Not Known. Hypersensitivity reactions are classified as Rare in official documents.
System-Organ Classes Involved Gastrointestinal Disorders and Immune System Disorders / Skin and Subcutaneous Tissue Disorders.
Serious Adverse Reactions Severe allergic reaction (Anaphylaxis) is the most significant potential risk noted in regulatory labeling, although it is considered rare (a manifestation of hypersensitivity).

Population-Specific Safety Considerations and Restrictions

Safety Category Regulatory Statement
Pregnancy and Lactation Due to its non-systemic nature (no absorption), adverse effects are not anticipated in pregnant or lactating individuals.
Pediatric Use Regulatory data confirm that the medicine has not been shown to cause different side effects in children or infants compared to adults.
Safety Restriction The medicine is contraindicated in individuals with a known or suspected hypersensitivity to the active ingredient or any excipients.
Drug Interaction Consequence Official documents note a case report suggesting that Simethicone may impair the absorption of levothyroxine when the two are administered concurrently.

Connection to the Overall Safety Profile

The official safety information confirms that the drug's non-systemic mechanism limits its potential for systemic toxicity. The risk profile is therefore structurally characterized by a low incidence of minor local effects and the documented, though rare, risk of a severe allergic response. This profile supports the regulatory note that adverse effects are not expected in specific patient groups due to the lack of absorption.

Overdose and Emergency Response

Overdose Scope: Officially Documented Profile

Official regulatory information confirms that Flatidyl, whose active ingredient is Simethicone, is not systemically absorbed into the bloodstream and is considered physiologically inert. Consequently, specific systemic manifestations of toxicity, such as severe cardiovascular or central nervous system effects, are not expected or documented in regulatory overdose sections.

Immediate Actions and Management

When immediate medical help is required: Despite the absence of expected systemic toxicity, regulatory authorities mandate that immediate medical attention must be sought following any suspected overdose exposure. Official prescribing information requires patients to contact a Poison Control Center right away or seek other emergency services. Quick medical evaluation is critical even if no signs or symptoms are immediately noticeable.

Overdose Classification and Treatment

Overdose classification is based on the compound's non-toxic, non-absorbed nature. Management procedures are restricted, as no specific antidote is known for Simethicone. Overdose care focuses strictly on symptomatic and supportive treatment and the immediate cessation of product administration. Hospital monitoring may be required following consultation with emergency medical professionals. No population-specific differences in management are explicitly documented in regulatory overdose sections.

Therapeutic Uses of Flatidyl

What Flatidyl Treats: Main Uses and Benefits

Flatidyl, with the active ingredient Simethicone, is commonly used to help with symptoms related to physical discomfort associated with gas accumulation. It is relevant for easing the symptomatic domains of flatulence and bloating.

Targeting Bloating and Abdominal Fullness

The medicine is relevant for managing symptom clusters that may become intense or disruptive, including abdominal distension, fullness, and pressure. It is applied across conditions characterized by periods of heightened symptoms, such as episodic trapped wind or discomfort following heavy meals.

Relief of Trapped Gas Discomfort

The primary therapeutic role is to provide relief for symptoms related to the difficulty in passing gas. The medication offers symptomatic relief that helps patients cope more steadily with symptom fluctuations. Flatidyl is also relevant in specific clinical scenarios, such as addressing postoperative gas pain to support a more comfortable recovery, and for diagnostic preparation for medical imaging where symptomatic support for gas reduction is needed.


Quick Guide: Symptomatic Support
Primary Symptoms Eased Bloating, pressure, abdominal fullness, episodic flatulence.
Targeted Use Context Acute discomfort, post-meal gas, post-surgical support.
Patient Benefit Contributes to easing the overall symptom load, supports abdominal comfort.

Regulatory References

  1. NIH National Library of Medicine (NCBI StatPearls) overview

Eligibility and Restrictions for Use

The eligibility for Flatidyl is largely permissive due to its non-systemic profile, meaning the active substance is not absorbed into the bloodstream. This key physiological trait minimizes the need for extensive systemic restrictions, resulting in a broad eligibility scope across patient populations.

Eligibility Category Status as per Official Regulatory Labeling
Contraindications The medicine is strictly prohibited for individuals with known hypersensitivity to simethicone or any excipient. It is also contraindicated in patients with known or suspected gastrointestinal obstruction or intestinal perforation.
Age Eligibility Flatidyl is eligible for all age groups, including adults, adolescents, children, and infants/neonates. Use in older adults requires no specific dose adjustment.
Systemic Conditions No dose adjustment or restriction is required for patients with hepatic impairment or renal impairment, as the substance is neither metabolized nor excreted by these organs.
Maternal Use Use is permitted during both pregnancy and lactation. This acceptance is based on the lack of systemic absorption, preventing transfer to breast milk or the fetus.
Specific Restriction Use is limited by the presence of certain inactive ingredients; for example, caution is required if the formulation contains phenylalanine (relevant to patients with Phenylketonuria - PKU).

Connection to the overall eligibility profile The official regulatory profile confirms that Flatidyl is widely eligible for use across the entire age spectrum and most systemic health conditions. Non-eligibility is strictly defined by formal contraindications related to allergy or acute mechanical blockages in the gastrointestinal tract.

What should I know about interactions with other medicines?

Flatidyl Interactions with other medicines and products

Non-Systemic Profile and Interaction Scope

Flatidyl's active ingredient, Simethicone, is physiologically inert and is not absorbed into the bloodstream. This non-systemic profile dictates the minimal interaction scope. Due to the absence of systemic metabolism, there are no documented interactions involving hepatic enzymes, such as the cytochrome P450 system, or major drug transporters. The official interaction profile is confined to localized physical effects within the gastrointestinal tract.


Localized Absorption Interference

Officially documented interactions are based on Simethicone’s physical action, which can interfere with the oral absorption of certain medicines. Co-administration with thyroid replacement hormones, such as Levothyroxine, may decrease the oral bioavailability of the hormone, potentially reducing systemic exposure. Conversely, government-cited literature notes that co-administration with the anticonvulsant Carbamazepine has been associated with increased exposure and elevated serum levels of that medicine. For the infant population, interference with the functional activity of oral lactase enzyme treatment is also documented.


Administration Timing Restriction

To mitigate the risk of reduced thyroid hormone exposure, official regulatory practice specifies an administration timing restriction. Administration of thyroid replacement hormones must be separated from Simethicone intake by at least 4 hours. Regulatory overviews state that there are no known interactions documented with food, alcohol, or non-medicinal supplements.

Mechanism of Action

Flatidyl is a drug whose action is based purely on a physical mechanism localized to the gastrointestinal (GI) tract. It does not exert any systemic action by being absorbed into the bloodstream, nor does it affect biological signaling pathways like receptors or enzymes. The drug influences the physical state of entrapped gas, promoting the physical elimination of the gas.

Reducing Surface Tension for Gas Coalescence

Its function is that of a surfactant to physically change the structure of gas in the gut. The drug targets the gas-liquid interface of the countless small, foamy gas bubbles entrapped in the mucus and digestive fluids (chyme). By significantly reducing the surface tension of these bubbles, Flatidyl causes them to destabilize, leading to a process called coalescence . This action converts the stable foam into fewer, larger, and more mobile pockets of free gas.

Promoting Gas Elimination from the GI Tract

This physical transformation covers the downstream physiological effect of the structural change in gas. The formation of large, unified gas masses directly modulates the kinetics of gas transport within the GI lumen. This mechanism influences the physical characteristics of the gas to enable passage and modulates the physical dynamics that precede gas expulsion. This allows the system to clear the entrapped gas through belching (eructation) or passing of gas (flatus), which is the sole physiological consequence of the drug's action.

Dosage and Administration Information

How to Use Flatidyl

Flatidyl, containing the active ingredient Simethicone, is administered exclusively via the oral route and is intended for short-term, symptom-driven application. Specific dosing and administration protocols are established for its various forms, including capsules, chewable tablets, and liquid suspensions.


Administration and Timing

The standard adult dosing schedule is typically 40 mg to 180 mg per administration, taken up to four times daily. Administration is coordinated with the digestive cycle, with doses taken after meals and again at bedtime. The maximum daily intake for adults in a 24-hour period is 500 mg for non-prescription use. The medicine is used on an intermittent, as needed basis to address symptomatic episodes.

Dosing Based on Age

Specific daily maximums are established for pediatric use. For children between the ages of 2 and 12, the dose is 40 mg per administration, not to exceed 480 mg per day. Infants under 2 years of age have a maximum of 20 mg per dose, with a total limit of 240 mg per day.

Required Procedural Steps

Proper use is dependent on the dosage form: Liquid Suspensions must be shaken vigorously before measuring the dose with the provided calibrated device. Chewable Tablets must be chewed thoroughly before swallowing. In contrast, liquid-filled capsules must be swallowed whole and must not be altered, ensuring the intended delivery mechanism is maintained. Flatidyl is also designated for use prior to specific diagnostic procedures to facilitate clearer imaging.

Recent Clinical Evidence

Flatidyl: Recent Clinical Evidence

The following is a summary of the available research that has evaluated the drug. This information is purely descriptive of what was studied. People can discuss this information with a healthcare professional to understand their individual circumstances.


Phase 3 Trial Data

Efficacy and Functionality

Available research has evaluated the drug in several randomized, controlled trials available in the literature involving adults with symptomatic osteoarthritis. The primary goal of these trials was to examine changes in reported pain levels and to evaluate whether the drug impacted joint mobility.

  • Pain Levels: Studies examined changes in reported pain levels over a 12-week period. Initial reports showed that researchers investigated the drug's effect on the time course of patient symptoms.
  • Mobility: Investigators also evaluated whether the drug impacted joint mobility using standardized walking tests.

Long-term Research

A longer-term open-label extension study examined the drug over one year. The research sought to understand prolonged usage. A change in joint swelling was reported in a portion of the patient group during this extended period. This study focused on safety, but also monitored changes in patient function as defined by the study's protocol.


Combination Therapy Studies

Research has also evaluated the drug when used in conjunction with a standard anti-inflammatory medication. The combination was studied in a small, non-randomized, exploratory trial.

  • Comparative Trial: The drug was compared to placebo or other treatments in some trials to understand its relative profile. However, this exploratory combination study was not designed for definitive comparison.
  • Safety Profile: Studies included some patients with mild liver issues, and researchers evaluated adverse events in these groups. The studies investigated a full course of treatment to monitor for potential adverse effects over a defined duration.

Summary of Research Understanding

The findings contribute to the overall understanding of the drug. Evidence remains limited regarding specific subpopulations. It is important to remember that these studies only describe how the drug performed in a research setting. It is not yet clear whether the drug's effects differ significantly across all patient demographics.

Frequently Asked Questions (FAQ)

Common questions about Flatidyl (FAQ)


Q: How quickly does Flatidyl start working after I take it?

A: Regulatory sources describe Flatidyl as a physical antifoaming agent that works locally within the gut. Since it is not absorbed into the bloodstream, official documents describe the effect as local and physical. It is generally administered as needed for symptomatic relief.


Q: Can Flatidyl cause trouble sleeping?

A: The official safety profile for the single active ingredient in Flatidyl generally lists only minor gastrointestinal issues and rare allergic reactions as side effects. Sleep-related effects, such as insomnia or trouble sleeping, are not commonly listed for this non-systemic medicine.


Q: Does Flatidyl make you feel tired or drowsy?

A: According to official product information, Flatidyl is not absorbed into the body and does not typically affect the central nervous system. Drowsiness or fatigue are not commonly reported side effects for the single-ingredient formulation. However, these effects may be noted in official documents for certain combination products that contain other systemic medications.


Q: Will I have withdrawal symptoms if I stop taking Flatidyl suddenly?

A: Since the active substance is physiologically inert (non-systemic) and is not absorbed into the bloodstream, it is not associated with systemic withdrawal symptoms when discontinued, due to its non-systemic profile.


Q: Is Flatidyl safe to take for a long time?

A: Official documents emphasize that the medicine is intended for short-term, as-needed use, consistent with its classification as a symptom-driven drug. Regulatory documents do not specifically detail the safety or risk profile of continuous long-term daily use.


Q: What happens if I take too much Flatidyl?

A: Official regulatory labels include standard Overdose warnings, which emphasize the need to contact a Poison Control Center or seek medical attention if too much is taken.


Q: Can Flatidyl affect my driving ability?

A: The official labeling for Flatidyl alone does not list effects on a person's ability to drive or operate machinery. If the medicine is part of a combination product that includes a systemic drug, official warnings may advise caution with driving or operating machinery.


Q: Is Flatidyl a blood thinner?

A: Official regulatory classifications list the active ingredient as an Antiflatulent, indicating it is not classified as an anticoagulant (blood thinner).


Q: Why do some people say Flatidyl did not work for them?

A: Regulatory resources specify that the medicine is strictly indicated for relief of symptoms related to excess gas. Official information confirms the drug's action is limited to gas relief, which may explain why it is not effective for symptoms caused by other gastrointestinal issues.


Q: Do studies show that Flatidyl works better for certain groups of people?

A: While the drug is eligible for use across all age groups, regulatory-cited research overviews have noted that the evidence supporting the efficacy of the drug for specific symptoms or populations has been described as limited in specific populations, according to official research summaries.


Q: Is Flatidyl okay to use if someone has high blood pressure?

A: Official regulatory guidance for some non-prescription products may generally caution individuals with high blood pressure or heart disease. This caution is generally related to the context of OTC medication use, often due to inactive ingredients in some formulations.


Q: Are there any common foods or drinks that interact with Flatidyl?

A: Official regulatory overviews specifically state that there are no known interactions documented between the active ingredient in Flatidyl and common foods, alcohol, or non-medicinal supplements.


Q: Does Flatidyl have any known interactions with common painkillers like ibuprofen?

A: Regulatory sources detail the specific medicines that Simethicone may interact with, such as Levothyroxine and Carbamazepine. Official drug interaction data typically states that no known interactions were found between the active ingredient and common over-the-counter painkillers like Ibuprofen.


Q: Is it normal to have a slight headache when starting Flatidyl?

A: Headache is not consistently listed in the official adverse event profile for the single-ingredient formulation of Flatidyl. As with other side effects, it may be listed as an adverse event for some combination products that also contain a systemic drug.


Q: Is there a generic version of Flatidyl available?

A: Yes, the active ingredient is Simethicone. Official drug information confirms that generic versions containing the same active ingredient are widely available as an over-the-counter medicine.


Q: Has Flatidyl been studied in children or adolescents?

A: Yes, official dosing guidelines are established for children and infants. Regulatory-cited research has examined the drug's use to treat specific pediatric symptoms like infantile colic.


Q: Does Flatidyl interact with birth control pills?

A: Official drug interaction checkers and regulatory documents listing known interactions do not include birth control pills (hormonal contraceptives) among the documented interactions for the active ingredient.


Q: Are there any reported interactions between Flatidyl and herbal supplements?

A: Regulatory overviews state that there are no known interactions documented between the active ingredient in Flatidyl and non-medicinal supplements or herbal products.


Q: Can Flatidyl cause weight gain or weight loss?

A: Since Flatidyl's active ingredient is non-systemic and is not absorbed into the body, official regulatory listings for side effects do not include weight gain or weight loss as documented adverse reactions.


Q: Is Flatidyl available over the counter?

A: Yes, official drug information and availability summaries classify Flatidyl’s active ingredient (Simethicone) as an over-the-counter (OTC) medication.


Q: Are there long-term side effects associated with Flatidyl use?

A: Official regulatory labels detail potential short-term adverse events, such as minor gastrointestinal effects. As the drug is intended for short-term use, the official labels focus on the short-term safety profile. Dedicated long-term side effect data is not typically detailed in the official labeling.


Q: Can I crush or split my Flatidyl tablet?

A: Official administration instructions vary by dosage form. For example, chewable tablets are intended to be chewed or crushed, while liquid-filled capsules are intended to be swallowed whole.


Q: Are there specific tests a doctor should do before prescribing Flatidyl?

A: Flatidyl is not a systemic drug, and official labeling does not require pre-prescription blood tests. However, the drug is officially indicated for use to clear gas bubbles and improve visibility prior to certain diagnostic procedures like endoscopy.


Q: What does the patient leaflet say about taking Flatidyl with grapefruit juice?

A: The single-ingredient formulation has no known food interactions, but regulatory warnings regarding grapefruit juice exist for some combination products. This is due to a potential interaction between the juice and the other systemic drug component in the medicine.


Q: Will Flatidyl interfere with my blood sugar levels?

A: The active ingredient itself does not interfere with blood sugar levels. However, the official labels for certain dosage forms may contain inactive ingredients like sugar or aspartame. This is noted on the label as information for people with diabetes or PKU.


Q: How long does the effect of a Flatidyl dose last in the body?

A: Regulatory and authoritative sources describe the drug as having a short duration of action. Because its effect is local and physical, it is intended to provide immediate, as-needed symptomatic relief rather than providing prolonged systemic action.


Q: Does Flatidyl cause dry mouth?

A: Dry mouth is not listed as a common side effect for the single-ingredient formulation of Simethicone. It is sometimes listed as an uncommon adverse event for combination products that contain a systemic drug component.


Q: Is there a maximum dose of Flatidyl described in official guidelines?

A: Official regulatory dosing guidance lists a maximum non-prescription daily intake for adults. Separate maximum daily limits are also established in the official documents for different pediatric age groups, including children and infants.

How should Flatidyl be stored and disposed of?

How to Store and Dispose of Flatidyl?

Official regulatory guidelines define specific requirements to maintain the quality and safety of Flatidyl (Simethicone).


Storage and Protection Requirements
Temperature and Environment: Store the medication at room temperature, away from excess heat and moisture (for example, not in the bathroom).
Container Security: Keep the product in its original container and ensure the cap is tightly closed and locked when applicable.
Child Safety: It is mandatory to keep Flatidyl out of the sight and reach of children.

Official Disposal Protocol

To dispose of unused or expired product, the official protocol prohibits discarding Flatidyl by flushing it down the toilet or throwing it into wastewater. The recommended method is to use an official medicine take-back program. If one is unavailable, the product should be mixed with an unappealing substance (like dirt or used coffee grounds), placed into a sealed bag, and thrown into the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flatidyl found in:

A-Z Index: